Skip to main content

Table 2 Expression of Cx30 on astrocytes after different HIV treatments

From: HIV-tat alters Connexin43 expression and trafficking in human astrocytes: role in NeuroAIDS

Cx30 expression in astrocytes (percentage of control, n = 3)

Treatment (virus)

7 days

14 days

21 days

28 days

HIVADA (20 ng/ml)

−12.3 ± 9.9*

−22.5 ± 8.9*

−32 ± 9.88*

−38.9 ± 7.9*

HIVJR-CSF (20 ng/ml)

−28.7 ± 6.8*

−32.7 ± 11*

−49.8 ± 14.6*

−65.5 ± 21.2*

Treatment (recombinant proteins)

6 h

12 h

24 h

48 h

Vif (1, 100, and 300 ng/ml)

−3.8 ± 1.06*

−5.99 ± 2.3*

−8.88 ± 4.5 *

−8.98 ± 5.6*

Gag (p55, p24, or p7: 1, 100, and 300 ng/ml)

No change

No change

No change

No change

Rev (1, 100, and 250 ng/ml)

No change

No change

No change

No change

Nef (1, 100, and 250 ng/ml)

−5.3 ± 3.2*

−8.6 ± 3.43*

−12.7 ± 6.6*

−14.9 ± 7.45*

Gp120 (1, 50, and 100 nM)

−3.44 ± 2.1*

−5.6 ± 5.4*

−8.88 ± 4.3*

−9.15 ± 3.3*

HIV-tat1–72 (1, 100, and 300 ng/ml)

−9.02 ± 3.3*

−10.5 ± 5.4*

−17.5 ± 3.9*

−28.1 ± 11.8*

IL-1β (10 ng/ml)

−21.7 ± 8.9*

−36.54 ± 9*

−51.3 ± 9.3*

−52.3 ± 21.5*

  1. Although we used three different concentrations for each HIV protein, no significant differences were detected among them. Thus, we combined the data from the three different concentrations
  2. *p ≤ 0.05 (n = 4)